Tumor cell plasticity: The challenge to catch a moving target

Journal of Gastroenterology

Volumn 49, Issue 4, 2014, Pages 618-627

  Schwitalla, Sarah ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

CSC model; Heterogeneity; Inflammatory microenvironment; Stochastic model; Tumor cell plasticity

Indexed keywords

CANCER STEM CELL; CANCER THERAPY; CARCINOGENESIS; GENETIC HETEROGENEITY; HUMAN; IMMUNE RESPONSE; INFLAMMATION; METABOLIC STRESS; METASTASIS; MICROFLORA; NONHUMAN; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PHENOTYPE; PLASTICITY; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; STOCHASTIC MODEL; TUMOR CELL; TUMOR RECURRENCE; BIOLOGICAL MODEL; CELL DEDIFFERENTIATION; GENETIC EPIGENESIS; GENETICS; NEOPLASMS; PATHOLOGY; PATHOPHYSIOLOGY; TUMOR MICROENVIRONMENT;

AUTACOID;

CELL DEDIFFERENTIATION; EPIGENESIS, GENETIC; HUMANS; INFLAMMATION MEDIATORS; MODELS, BIOLOGICAL; NEOPLASMS; NEOPLASTIC STEM CELLS; PHENOTYPE; TUMOR MICROENVIRONMENT;

EID: 84899944962     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-014-0943-1     Document Type: Review

References (108)

1. Broadbridge VT, et al. Do metastatic colorectal cancer patients who present with late relapse after curative surgery have a better survival? Br J Cancer. 2013;109(5):1338-43.
2. Honeth G, et al. The CD44 +/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 2008;10(3):R53.
3. Stoecklein NH, et al. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell. 2008;13(5):441-53. (Pubitemid 351609446)
4. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell. 2012; 21(3):283-96.
5. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011;17(3):313-9.
6. Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest. 2010;120(1):41-50.
7. Bakhoum SF, Compton DA. Chromosomal instability and cancer: a complex relationship with therapeutic potential. J Clin Invest. 2012;122(4):1138-43.
8. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer. 2012;12(5):323-34.
9. Gerlinger M, Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer. 2010;103(8):1139-43.
10. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res. 2012;72(19):4875-82.
11. Gillies RJ, Verduzco D, Gatenby RA. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer. 2012;12(7):487-93.
12. Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell. 2012;10(6):717-28.
13. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730-7. (Pubitemid 27298715)
14. Dalerba P, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA. 2007;104(24):10158-63. (Pubitemid 47175279)
15. O'Brien CA, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445(7123):106-10. (Pubitemid 46067310)
16. Ricci-Vitiani L, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445(7123):111-5. (Pubitemid 46067311)
17. Shmelkov SV, et al. CD133 expression is not restricted to stem cells, and both CD133 ? and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest. 2008;118(6):2111-20. (Pubitemid 351872330)
18. Perez-Losada J, Balmain A. Stem-cell hierarchy in skin cancer. Nat Rev Cancer. 2003;3(6):434-43. (Pubitemid 37328847)
19. Kreso A, et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science. 2013;339(6119):543-8.
20. Mani SA, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704-15. (Pubitemid 351636299)
21. Colotta F, et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30(7):1073-81.
22. Wang TL, et al. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci USA. 2004;101(9):3089-94.
23. Salk JJ, Fox EJ, Loeb LA. Mutational heterogeneity in human cancers: origin and consequences. Annu Rev Pathol. 2010;5:51-75.
24. Ding L, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481(7382):506-10.
25. Walter MJ, et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med. 2012;366(12):1090-8.
26. Schuh A, et al. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood. 2012;120(20):4191-6.
27. Navin N, et al. Tumour evolution inferred by single-cell sequencing. Nature. 2011;472(7341):90-4.
28. Nik-Zainal S, et al. The life history of 21 breast cancers. Cell. 2012;149(5):994-1007.
29. Jones S, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321(5897):1801-6.
30. Yachida S, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010; 467(7319):1114-7.
31. Shackleton M, et al. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell. 2009;138(5):822-9.
32. Egeblad M, Rasch MG, Weaver VM. Dynamic interplay between the collagen scaffold and tumor evolution. Curr Opin Cell Biol. 2010;22(5):697-706.
33. Picchio M, et al. Intratumoral spatial distribution of hypoxia and angiogenesis assessed by 18F-FAZA and 125I-Gluco-RGD autoradiography. J Nucl Med. 2008;49(4):597-605. (Pubitemid 351520608)
34. Friedl P, Wolf K. Plasticity of cell migration: a multiscale tuning model. J Cell Biol. 2010;188(1):11-9.
35. Sanz-Moreno V, Marshall CJ. The plasticity of cytoskeletal dynamics underlying neoplastic cell migration. Curr Opin Cell Biol. 2010;22(5):690-6.
36. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21(3):309-22.
37. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501(7467):346-54.
38. Wilting RH, Dannenberg JH. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Drug Resist Updat. 2012;15(1-2):21-38.
39. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29(34):4741-51.
40. Baylin SB. Resistance, epigenetics and the cancer ecosystem. Nat Med. 2011;17(3):288-9.
41. Chaffer CL, et al. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell. 2013;154(1):61-74.
42. Schwitalla S, et al. Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. Cancer Cell. 2013;23(1):93-106.
43. Acharyya S, et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell. 2012;150(1):165-78.
44. Landsberg J, et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature. 2012;490(7420):412-6.
45. Asiedu MK, et al. TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Res. 2011;71(13):4707-19.
46. Knutson KL, et al. Immunoediting of cancers may lead to epithelial to mesenchymal transition. J Immunol. 2006;177(3): 1526-33.
47. Santisteban M, et al. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res. 2009;69(7):2887-95.
48. Oeckinghaus A, Hayden MS, Ghosh S. Crosstalk in NF-kappaB signaling pathways. Nat Immunol. 2011;12(8):695-708.
49. Grivennikov SI. Inflammation and colorectal cancer: colitisassociated neoplasia. Semin Immunopathol. 2013;35(2):229-44.
50. Greten FR, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004;118(3):285-96. (Pubitemid 39061110)
51. Shaked H, et al. Chronic epithelial NF-kappaB activation accelerates APC loss and intestinal tumor initiation through iNOS up-regulation. Proc Natl Acad Sci USA. 2012;109(35): 14007-12.
52. Motz GT, Coukos G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol. 2011;11(10):702-11.
53. Hansen W, et al. Neuropilin 1 deficiency on CD4 + Foxp3 + regulatory T cells impairs mouse melanoma growth. J Exp Med. 2012;209(11):2001-16.
54. Yao Z, et al. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci USA. 2010;107(35):15535-40.
55. Creighton CJ, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA. 2009;106(33):13820-5.
56. DeNardo DG, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011;1(1):54-67.
57. Chaffer CL, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci USA. 2011;108(19):7950-5.
58. Vermeulen L, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol. 2010;12(5):468-76.
59. Schwitalla S, et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell. 2013;152(1-2):25-38.
60. Scheel C, et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell. 2011;145(6):926-40.
61. Quante M, et al. Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell. 2012;21(1):36-51.
62. Quante M, et al. Barrett esophagus: what a mouse model can teach us about human disease. Cell Cycle. 2012;11(23): 4328-38.
63. Kim TH, et al. Broadly permissive intestinal chromatin underlies lateral inhibition and cell plasticity. Nature. 2014. doi:10.1038/nature12903
64. Berdasco M, Esteller M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell. 2010;19(5):698-711.
65. Rai K, et al. DNA demethylation in zebrafish involves the coupling of a deaminase, a glycosylase, and gadd45. Cell. 2008;135(7):1201-12.
66. Rai K, et al. DNA demethylase activity maintains intestinal cells in an undifferentiated state following loss of APC. Cell. 2010;142(6):930-42.
67. Nadauld LD, et al. Adenomatous polyposis coli control of retinoic acid biosynthesis is critical for zebrafish intestinal development and differentiation. J Biol Chem. 2004;279(49):51581-9. (Pubitemid 40017909)
68. Blanc V, et al. Deletion of the AU-rich RNA binding protein Apobec-1 reduces intestinal tumor burden in Apc(min) mice. Cancer Res. 2007;67(18):8565-73. (Pubitemid 47437431)
69. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature. 1983;301(5895):89-92. (Pubitemid 13154475)
70. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4):683-92. (Pubitemid 46273572)
71. Esteller M. Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer. 2007;96(Suppl): R26-30.
72. Fraga MF, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005;37(4):391-400.
73. van Roon EH, et al. BRAF mutation-specific promoter methylation of FOX genes in colorectal cancer. Clin Epigenetics. 2013;5(1):2.
74. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 2006;6(2):107-16. (Pubitemid 43361543)
75. Huang S, et al. MED12 controls the response to multiple cancer drugs through regulation of TGF-beta receptor signaling. Cell. 2012;151(5):937-50.
76. Quintana E, et al. Efficient tumour formation by single human melanoma cells. Nature. 2008;456(7222):593-8.
77. Hoek KS, et al. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res. 2008;68(3):650-6. (Pubitemid 351206739)
78. Quintana E, et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell. 2010;18(5):510-23.
79. Boiko AD, et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature. 2010;466(7302):133-7.
80. Roesch A, et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell. 2010;141(4):583-94.
81. Sharma SV, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141(1):69-80.
82. Morel AP, et al. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One. 2008;3(8):e2888.
83. Lopez-Garcia C, et al. Intestinal stem cell replacement follows a pattern of neutral drift. Science. 2010;330(6005):822-5.
84. van Es JH, et al. Dll1 + secretory progenitor cells revert to stem cells upon crypt damage. Nat Cell Biol. 2012;14(10):1099-104.
85. Buczacki SJ, et al. Intestinal label-retaining cells are secretory precursors expressing Lgr5. Nature. 2013;495(7439):65-9.
86. Schepers AG, et al. Lineage tracing reveals Lgr5 + stem cell activity in mouse intestinal adenomas. Science. 2012;337(6095):730-5.
87. Thiery JP, et al. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871-90.
88. Spaderna S, et al. A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology. 2006;131(3):830-40. (Pubitemid 44307069)
89. Prall F, Weirich V, Ostwald C. Phenotypes of invasion in sporadic colorectal carcinomas related to aberrations of the adenomatous polyposis coli (APC) gene. Histopathology. 2007;50(3):318-30. (Pubitemid 46169416)
90. Li G, et al. Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene. 2001;20(56):8125-35. (Pubitemid 34028337)
91. Toh B, et al. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol. 2011;9(9):e1001162.
92. Bornstein P, McPherson J, Sage EH. Synthesis and secretion of structural macromolecules by endothelial cells in culture. In: Nossel HL, Vogel HJ, editors. Pathobiology of the endothelial cell, P&S biomedical sciences symposia, vol 6, 1982. pp. 215-228
93. Nelson CM, et al. Change in cell shape is required for matrix metalloproteinase-induced epithelial-mesenchymal transition of mammary epithelial cells. J Cell Biochem. 2008;105(1):25-33.
94. Xu R, Boudreau A, Bissell MJ. Tissue architecture and function: dynamic reciprocity via extra- and intra-cellular matrices. Cancer Metastasis Rev. 2009;28(1-2):167-76.
95. Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer. 2008;8(12):967-75.
96. Allinen M, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004;6(1): 17-32. (Pubitemid 38903159)
97. Polyak K, Haviv I, Campbell IG. Co-evolution of tumor cells and their microenvironment. Trends Genet. 2009;25(1):30-8.
98. Gupta PB, et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell. 2011;146(4):633-44.
99. Nakasone ES, et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell. 2012;21(4):488-503.
100. Kioi M, et al. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest. 2010;120(3):694-705.
101. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331(6024):1565-70.
102. Meyer C, et al. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci USA. 2011;108(41):17111-6.
103. Soudja SM, et al. Tumor-initiated inflammation overrides protective adaptive immunity in an induced melanoma model in mice. Cancer Res. 2010;70(9):3515-25.
104. Brogan J, et al. Imaging molecular pathways: reporter genes. Radiat Res. 2012;177(4):508-13.
105. Glunde K, Bhujwalla ZM. Metabolic tumor imaging using magnetic resonance spectroscopy. Semin Oncol. 2011;38(1): 26-41.
106. Lagadec C, et al. Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment. Breast Cancer Res. 2010;12(1):R13.
107. Bao S, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756-60. (Pubitemid 44949604)
108. Dylla SJ, et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One. 2008;3(6):e2428.